Comparative Pharmacology
Head-to-head clinical analysis: HYDRO D versus METHYCLOTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDRO D versus METHYCLOTHIAZIDE.
HYDRO-D vs METHYCLOTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thiazide diuretic that inhibits the sodium-chloride symporter (NCC) in the distal convoluted tubule, reducing sodium and water reabsorption and increasing potassium excretion.
Thiazide-like diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reduces peripheral vascular resistance.
25-100 mg orally once daily in the morning.
2.5-10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 5.6 to 15 hours; prolonged in renal impairment and in patients with heart failure.
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin."
Clinical Note
moderateMethyclothiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life: ~40 hours (range 30-50 h); due to extensive tubular reabsorption, half-life is prolonged in renal impairment and elderly, allowing once-daily dosing
Renal: approximately 50% as unchanged drug; biliary/fecal: approximately 50% as metabolites and minor unchanged drug.
Primarily renal (70-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal (<10%)
Category C
Category C
Thiazide Diuretic
Thiazide Diuretic
Methyclothiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin."